Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Authors

Matthew A Powell, Washington University School of Medicine in St. Louis
Carolyn McCourt, Washington University School of Medicine in St. Louis
et al.

Journal

Gynecologic Oncology

Publication Date

1-1-2025

Volume

192

First Page

40

Last Page

49

Document Type

Open Access Publication

DOI

10.1016/j.ygyno.2024.10.022

Rights and Permissions

Powell MA, Cibula D, O'Malley DM, Boere I, Shahin MS, Savarese A, Chase DM, Gilbert L, Black D, Herrstedt J, Sharma S, Kommoss S, Gold MA, Thijs AM, Ring K, Bolling MF, Buscema J, Gill SE, Nowicki P, Nevadunsky N, Callahan M, Willmott L, McCourt C, Billingsley C, Ghamande SA, He Z, Balas MM, Stevens S, Fleming E, Mirza MR. Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). Gynecol Oncol. 2025 Jan;192:40-49. doi: 10.1016/j.ygyno.2024.10.022. © 2025 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Recommended Citation

Powell, Matthew A; McCourt, Carolyn; and et al., "Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)." Gynecologic Oncology. 192, 40 - 49. (2025).
https://digitalcommons.wustl.edu/oa_4/5847

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.